As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now.
A few enterprising businesses are marketing themselves differently.
Morgan Stanley is betting on these stocks to benefit from the AI megatrend.
AI is a key growth driver for both of these stocks owned by the Gates Foundation Trust.
The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven...
2024 is going to be a sizzler in the biopharma sector.
Its groundbreaking work is winning it some powerful fans, but it's still risky.
There's more to the AI boom than Microsoft and ChatGPT.
Cathie Wood and Bill Gates like this stock, too.
Its future could be bright, but don't get too attached to its successes right now.